Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
2,845 total articles
MDA Space ($32.56) trades like a high-growth story but now carries stretched multiples (P/E 50.2, P/B 4.0) and declining technicals. With price well below short-term moving averages, heavy short interest on recent volume spikes, and upcoming execution-dependent milestones across Robotics and Satellite Systems, the easy upside is largely priced in. …
Greg Abel's early actions as CEO - a personal $15M buy and the restart of repurchases - create an actionable long trade on Berkshire Hathaway. Valuation looks reasonable (P/E ~15, P/B ~1.44) while FCF and a $1.04T market cap anchor upside. This trade targets a rebound toward the upper half of the 52-week range over a 180-trading-day horizon, with a…
Micron is trading well below its recent highs after a market pullback, but underlying fundamentals - low leverage, double-digit free cash flow, and sold-out HBM capacity - look very similar to the early stages of Nvidia's profit re-rating. This is a tradeable long: enter at $405.00, stop at $360.00, target $550.00 over a long-term, 180 trading day …
Trinity Capital (TRIN) offers a compelling income entry today: a monthly $0.17 dividend (14%+ yield) backed by a growing investment book, modest valuation (P/B ~1.07, P/E ~7.3) and a market cap around $1.2B. The trade targets mean reversion toward recent highs while collecting outsized cash distribution; downside is controlled with a sub-$13 stop i…
Apogee Therapeutics (APGE) is a clinical-stage biotech that just put itself squarely in the market's spotlight: compelling 16-week Phase 2 data, a long half-life TSLP program enabling infrequent dosing, and a 52-week APEX readout on 03/23/2026. This trade idea lays out a defined long with entry, stop and target for a long-term swing (180 trading da…
Novartis ($148.09) is executing against a diversified growth playbook: bolt-on M&A (SNV4818), dermatology approvals, and external licensing add near-term revenue and long-term optionality. Valuation is reasonable for a large-cap pharma with $8.17B FCF and a $313.9B market cap. Trade long with a $170 target and $135 stop while monitoring clinical re…
Lyell's dual-targeting CAR-T (ronde-cel / LYL314) has delivered impressive early response data and the company just closed a $50M tranche that extends runway into Q2 2027. The story remains fundamentally attractive, but the path to commercialization and financing risk keep this a high-volatility trade. We outline a tactical long with strict stops a…
SoFi (SOFI) has been punished recently by a secondary offering, a high-profile short report and crypto-related headline risk. The business, however, still posted $3.61B in 2025 revenue (+35% YoY), 13.7M members (+35%) and reported GAAP profitability across recent quarters. With a market cap near $21.9B, conservative leverage and insider buying, the…
Cloudflare is expensive on headline multiples, but its role as global edge infrastructure and recent momentum make a tactical add attractive. I personally loaded at $170 and plan to add if shares pull back to $210, with a stop at $195 and a primary target near the 52-week high at $260. The trade is driven by accelerating enterprise deal flow, impro…
Nvidia remains the engine of the AI data-center cycle: $4.33T market cap, exceptional ROE and free cash flow, and low leverage. Near-term selling has pushed momentum indicators into neutral-to-bearish territory, but fundamentals and catalysts (AI demand, new energy partnerships, industry spend signals) argue for a mid-term rebound. I outline a clea…
Brookfield Infrastructure offers a near-5% distribution yield, diversified regulated and contracted cash flows, and optional upside from growing AI-related data center demand. The balance between reliable yields and price optionality — with a market cap of roughly $16.5B and a 52-week range of $25.72-$40.32 — creates a pragmatic long trade for inco…
Rivian just landed a material commercial and capital partnership with Uber and is rolling into the mass-market R2 launch. The deal reduces funding uncertainty and creates a large potential buyer for up to 50,000 autonomous vehicles; combine that with improving technical momentum and you have a tradable long setup with defined risk-reward.
Salesforce is trading near $195 while the market digests headlines about AI displacing software subscriptions. That narrative misses the point: Salesforce is structurally advantaged as enterprises move to agentic AI because it owns customer data, identity plumbing and an expanding AI revenue stream. With $14.4B in free cash flow, a market cap of ~$…
Marvell sits at the junction of two durable trends: the shift to custom AI processors and the compounding need for higher-bandwidth data-center interconnects. Trading at roughly $90 with a market cap near $79B, the stock offers a leveraged way to play AI infrastructure without buying a pure GPU vendor. This trade idea lays out entry, stop, targets …
XPLR Infrastructure (XIFR) is trading at a steep price-to-book discount (P/B ~0.29) despite owning contracted battery, solar, and wind cash flows. The equity looks actionable as a long-term trade around $10.10, but heavy leverage (debt-to-equity ~1.98), negative free cash flow, and active securities litigation mean this is a conditional opportunity…
Ares Management (ARES) trades closer to its 52-week low while its credit platform keeps adding assets and yield. This trade buys ARES on weakness as a way to get diversified private-credit exposure and an above-index yield, with clear entry, stop and target levels tied to fundamental catalysts.
Blue Owl’s shares trade near $9 with a headline dividend yield close to 10% after a private-credit liquidity scare. The pullback is painful but targeted liquidity management, large market cap scale ($14.24B) and recent management actions create a defined asymmetric trade: collect high current yield while risking limited capital if stress stabilizes…
HydroGraph Clean Pwr (HGRAF) is an OTC micro-cap developing graphene-related technology. Price action and volume have picked up in March 2026 while technicals show a mixed picture. This trade idea outlines a long-biased plan with clear entry, stop and target levels, and a risk-minded view appropriate for an OTC play with limited public disclosures.
Novo Nordisk looks dangerously exposed: cheap semaglutide generics from India, a troubled pipeline headline and stretched capital-market expectations have already crushed the stock from a $81 52-week high to the mid-$30s. Combine a heavy institutional short interest, weakening technicals and near-term legal/regulatory headlines, and you have a trad…
Fortinet's combination of durable free cash flow ($2.23B), high retention and recent revenue acceleration (15.1% reported for Q4 2025), and product roadmaps layered with AI capabilities argue for upside from current levels. Valuation is full but not irrational: market cap roughly $61B, P/E around 33x and P/FCF near 27x. This trade targets near-term…
Micron is the biggest pure-play memory beneficiary of an HBM shortage tied to AI infrastructure. Strong revenue/earnings beats, robust free cash flow and low leverage support a bull case that could take the stock to ~$890 (implied $1T market cap). Trade plan provided with entry at $416.00, stop at $360.00 and a long-term target of $890.00 (180 trad…
PayPal is trading at roughly an 8x P/E with robust free cash flow and an enterprise value to EBITDA near 6x. Recent governance shocks and a class-action filing have left the stock cheap. This trade idea lays out a clear entry, stop and target with a 180-trading-day horizon and balanced risk framework.
Microsoft ($MSFT) has been marked down with the broader tech selloff, but fundamentals remain intact: $77.4B of free cash flow, ROE ~30.5%, and a strong balance sheet (debt/equity ~0.10). Technicals show short-term oversold conditions (RSI ~36) while valuations (PE ~23.9, P/FCF ~36.6) still price in growth. This trade idea advocates a mid-term long…
PayPal's stock trades like a company in distress while its cash generation and balance-sheet metrics still look solid. With a market cap near $42B, free cash flow of $5.56B and an implied P/E around 8, we think a measured long makes sense. This trade bets on valuation mean reversion, stabilization under new management and a de-risking of the litiga…
Palisade Bio is an underfollowed clinical-stage biotech developing oral therapies for post-operative and inflammatory gut disorders. With a market cap near $281M, ~ $28.8M in cash, a Canadian patent allowance for its PALI-2108 candidate, and Phase 1 expected progress, the risk/reward skews toward upside for catalytic readouts. Initiate a speculativ…
